Previous Close | 1,164.46 |
Open | 1,160.74 |
Bid | 1,153.07 x 100 |
Ask | 1,153.92 x 100 |
Day's Range | 1,150.02 - 1,170.58 |
52 Week Range | 769.19 - 1,211.20 |
Volume | |
Avg. Volume | 465,167 |
Market Cap | 127.14B |
Beta (5Y Monthly) | 0.12 |
PE Ratio (TTM) | 30.58 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1,” the […]